DrugPatentWatch Database Preview
Drugs in Development Information for CCX168
Email this page to a colleague
» See Plans and PricingWhat is the development status for investigational drug CCX168?
CCX168 is an investigational drug.
There have been 7 clinical trials for CCX168.
The most recent clinical trial was a Phase 2 trial, which was initiated on December 1st 2016.
The most common disease conditions in clinical trials are Vasculitis, Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis, and Hemolytic-Uremic Syndrome. The leading clinical trial sponsors are ChemoCentryx, Mario Negri Institute for Pharmacological Research, and [disabled in preview].
There are nine US patents protecting this investigational drug and one hundred and one international patents.
Summary for CCX168
| US Patents | 9 |
| International Patents | 101 |
| US Patent Applications | 22 |
| WIPO Patent Applications | 7 |
| Japanese Patent Applications | 0 |
| Clinical Trial Progress | Phase 2 (2016-12-01) |
| Vendors | 12 |
Recent Clinical Trials for CCX168
| Title | Sponsor | Phase |
|---|---|---|
| Evaluation of Safety and Efficacy of Avacopan in Subjects With Moderate to Severe Hidradenitis Suppurativa | ChemoCentryx | Phase 2 |
| Controlled Trial Evaluating Avacopan in C3 Glomerulopathy | ChemoCentryx | Phase 2 |
| A Phase 3 Clinical Trial of CCX168 (Avacopan) in Patients With ANCA-Associated Vasculitis | ChemoCentryx | Phase 3 |
Clinical Trial Summary for CCX168
Top disease conditions for CCX168
Top clinical trial sponsors for CCX168
US Patents for CCX168
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| CCX168 | Start Trial | C5aR antagonists | ChemoCentryx, Inc. (Mountain View, CA) | Start Trial |
| CCX168 | Start Trial | Processes and intermediates in the preparation of C5aR antagonists | ChemoCentryx, Inc. (Mountain View, CA) | Start Trial |
| CCX168 | Start Trial | Soluble C5aR antagonists | ChemoCentryx, Inc. (Mountain View, CA) | Start Trial |
| CCX168 | Start Trial | Treatment of inflammatory diseases with inhibitors of C5a activity | InflaRx GmbH (Jena, DE) | Start Trial |
| CCX168 | Start Trial | C5aR antagonists | Chemocentryx, Inc. (Mountain View, CA) | Start Trial |
| CCX168 | Start Trial | C5aR antagonists | ChemoCentryx, Inc. (Mountain View, CA) | Start Trial |
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for CCX168
| Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
|---|---|---|---|---|
| CCX168 | Argentina | 077162 | 2028-12-22 | Start Trial |
| CCX168 | Australia | 2009330194 | 2028-12-22 | Start Trial |
| CCX168 | Brazil | 112012033075 | 2028-12-22 | Start Trial |
| CCX168 | Brazil | PI0923384 | 2028-12-22 | Start Trial |
| CCX168 | Canada | 2747522 | 2028-12-22 | Start Trial |
| CCX168 | Canada | 2965223 | 2028-12-22 | Start Trial |
| >Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |
